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Continual reassessment method for dose
escalation clinical trials in oncology: a
comparison of prior skeleton approaches
using AZD3514 data
Gareth D. James1,2, Stefan N. Symeonides2,3, Jayne Marshall2, Julia Young2 and Glen Clack2*
Abstract
Background: The continual reassessment method (CRM) requires an underlying model of the dose-toxicity
relationship (“prior skeleton”) and there is limited guidance of what this should be when little is known about this
association. In this manuscript the impact of applying the CRM with different prior skeleton approaches and the 3 +
3 method are compared in terms of ability to determine the true maximum tolerated dose (MTD) and number of
patients allocated to sub-optimal and toxic doses.
Methods: Post-hoc dose-escalation analyses on real-life clinical trial data on an early oncology compound
(AZD3514), using the 3 + 3 method and CRM using six different prior skeleton approaches.
Results: All methods correctly identified the true MTD. The 3 + 3 method allocated six patients to both sub-optimal
and toxic doses. All CRM approaches allocated four patients to sub-optimal doses. No patients were allocated to
toxic doses from sigmoidal, two from conservative and five from other approaches.
Conclusions: Prior skeletons for the CRM for phase 1 clinical trials are proposed in this manuscript and applied to a
real clinical trial dataset. Highly accurate initial skeleton estimates may not be essential to determine the true
MTD, and, as expected, all CRM methods out-performed the 3 + 3 method. There were differences in performance
between skeletons. The choice of skeleton should depend on whether minimizing the number of patients allocated
to suboptimal or toxic doses is more important.
Trial registration: NCT01162395, Trial date of first registration: July 13, 2010.
Keywords: Clinical trial, Phase 1, Continual reassessment method, Skeleton, Bayesian, Oncology
Background
The purpose of phase 1 clinical trials is to determine the
recommended dose for further clinical testing [1], whilst
being efficient by minimizing the number of patients
and preserving safety [2]. Trials in cancer are different
to those for other indications as patients have a meta-
static disease and have exhausted other treatment op-
tions [3]. Because of this, potential efficacy is also of
major importance to patients, [4–6] investigators [3]
and regulatory authorities [7], thus minimising the
number of patients allocated to suboptimal doses is also
important. Despite this, literature reviews found less
than 5 % of patients in oncology trials experience a re-
sponse [3, 8] and this number is decreasing [3]. The 3 +
3 method is rule based and the most common design
for dose escalation studies, with over 96 % of studies
using this method [1], but is not statistically efficient as
it does not use all available data to recommend the next
dose level to allocate [9]. This leads to more patients
than necessary receiving suboptimal doses [10, 11] and
limited ability to detect the MTD.
Model-based designs such as the continual reassessment
method (CRM) [12] offer an alternative to rule-based
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designs and use Bayesian models or maximum likeli-
hood estimation (MLE). Both rule and model-based de-
signs aim to determine the maximum tolerated dose
(MTD), the highest dose at which a pre-specified pro-
portion of patients experience a dose-limiting toxicity
(DLT). A DLT is a side effect of a treatment that is
serious enough to raise concern about that dose and its
definition is decided prior to dosing. Unlike rule-based
designs, model-based designs use toxicity data from all
dose levels, so are more statistically efficient [1]. There
are around 100 publications which demonstrate the ad-
vantage of using model based methods over rule based
methods in terms of efficiency and ethical considerations
[13]. In particular, studies have found that, compared to
the 3 + 3 method, the CRM allocates fewer patients to
suboptimal [9] and harmful doses [11, 14] and identifies
the true MTD a higher proportion of the time [15, 16],
reducing the likelihood of making a costly and potentially
unsafe decision.
Despite the benefits of model-based methods over rule-
based methods, literature reviews have identified that these
methods were only used in 3.3 % of phase 1 trials between
2007 and 2008 [1] and 1.6 % of trials between 1991 and
2006 [13]. Reasons for the low uptake of these models
could include hesitancy to apply a complicated”black box”
algorithm [17], or a lack of practical guidance for imple-
menting these methods [2]. Model-based methods require
pre-specification of the dose-toxicity model, which consists
of estimates of the prior probability of experiencing a DLT
for each dose (skeleton) and the prior distribution which is
the underlying confidence in the prior probabilities [2].
The prior distribution has been investigated previously
[18]. When there is substantial knowledge of the dose-
toxicity relationship from pre-clinical or clinical studies, it
can be translated into an estimate of the prior probabilities
[19]. However substantial knowledge may not always be
available or the translatability of the preclinical data can be
in doubt. In this situation, choice of prior probabilities is a
particular challenge [19, 20] and prior probabilities may
not be accurate [1]. We found limited guidance on which
standard prior probabilities should be used when there is
limited knowledge on dose-toxicity, which is a clear area of
need. It should be noted however, that Lee Cheung 2009
proposed using indifference intervals to determine prior
probabilities, rather than specifying prior probabilities, an
approach which deserves some consideration [2].
We sought to compare the defined MTD and number
of patients allocated to sub-optimal and toxic doses ob-
tained using the Bayesian model CRM, with different prior
skeleton approaches, and the 3 + 3 method. We did so by
doing a post-hoc dose-escalation analysis using real life
data from the AZD3514 study, a phase 1 clinical trial in
patients with metastatic castration resistant prostate can-
cer (CRPC) [21]. We provide a practical example of this
method using our data (Appendix) and provide recom-
mendations in the discussion to improve the uptake of
these methods.
Methods
The source dataset was a study of patients with metastatic
CRPC being given AZD3514, a selective androgen receptor
downregulator [21]. Patients received doses of AZD3514
monotherapy of 100 mg once daily (QD), 250 mg QD,
500 mg QD, 1000 mg QD, 1000 mg twice daily (BID) or
2000 mg BID. At the end of that study, no patients below
2000 mg BID had met the pre-determined DLT criteria.
However moderate or greater nausea and vomiting were
significant tolerability concerns and caused higher doses to
be considered non-tolerable [22]. Therefore, moderate or
greater (CTCAE grade 2+) nausea and vomiting was retro-
spectively defined as a DLT. The result is a relatively
unique real-world dataset of dose escalations unaffected by
the subsequently-lowered DLT criteria, allowing complete
capture of DLTs at each dose level up to and past MTD,
with dose-doubling maintained throughout.
We created an exploratory dataset with the first six
patients who completed DLT assessment from each dose
level between 250 mg QD and 1000 mg BID and all four
patients on 2000 mg BID. The lowest dose was omitted
for simplicity, especially because it was not following a
dose-doubling regime. All four patients on 2000 mg BID
experienced a DLT, so it was expected that data from
these four patients would be sufficient for this dose level.
Because nausea and vomiting were associated with in-
creasing dose and no patients experienced a protocol de-
fined DLT, we defined DLT as moderate/severe/very
severe (CTCAE grade 2 to 4) nausea or vomiting occur-
ring at any time during treatment. Using this dataset we
will deduce the MTD, as the highest dose where the
proportion of patients experiencing a DLT is below the
target toxicity dose. Doses below the MTD will be con-
sidered suboptimal, and, doses above the MTD will be
considered as intolerable. This method reflects how the
MTD is chosen in clinical practice.
The 3 + 3 design involves allocating three patients to
the initial dose level. If no patients experience a DLT,
the dose level is considered safe and the next higher
dose is explored. If two or more patients experience a
DLT, the dose level is considered toxic and the trial can
proceed to a lower dose. If one patient experiences a
DLT, then three more patients are allocated to the same
dose. If no further patients experience a DLT, the dose
level is considered safe but if one or more further pa-
tients experience a DLT, the dose level is considered
non-tolerated. The MTD is the highest dose tolerated by
>4/6 of patients that received it (i.e. at least 5 of the 6
tested). For more information refer to Jaki et al. [19]
who provide a schematic display of this method.
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The CRM uses a Bayesian model which assumes the
probability of experiencing a DLT increases with dose
[19]. We need to choose the dose toxicity model, skeleton,
prior distribution and target toxicity level. A dose-toxicity
model should be chosen which is consistent with our a
priori belief of the relationship between dose and toxicity.
Examples of common dose-toxicity models include em-
piric [2] and logistic [18]. The prior distribution represents
the initial confidence we have of the dose-toxicity relation-
ship and many examples of these distributions are pro-
vided by Chevret [18]. The target toxicity level is the
maximum proportion of patients experiencing a DLT that
is acceptable given the risk benefit profile. Initial estimates
of prior probabilities of DLT for each dose form the initial
dose toxicity curve (skeleton). The curve is continually
updated as new patient dose-toxicity information is in-
cluded. If one extra patient who experienced a DLT is
included in the model, the dose toxicity curve shifts up-
wards indicating an increase in the probability of experi-
encing a DLT at all doses. If one extra patient who did not
experience a DLT is included in the model, the dose tox-
icity curve shifts downwards, indicating a decrease in the
probability of experiencing a DLT at all doses. After the
model is updated, the CRM will recommend that the next
patient(s) are allocated the dose which is closest to the
target toxicity level. If one extra patient is added, because
the curve shifts are dependent on DLTs, the next recom-
mended dose cannot increase if a DLT is experienced, and
cannot decrease if a DLT is not experienced. This is dem-
onstrated clearly in Appendix. There are various stopping
rules to determine the MTD, the simplest of which is
stopping after six patients have received the same dose.
Goodman’s modification involved enrolling one to three
patients to each cohort, starting with the lowest dose and
escalating one dose each time until the first DLT is ex-
perienced [11]. After this, the CRM method is used to
determine the next dose and all further doses. The CRM
method with this modification is commonly known as the
extended CRM [15]. This ensures some patients receive
the lowest dose which preserves safety, making the initial
dose independent of the prior probabilities. If the CRM is
used to identify the first dose it will recommend the one
with the initial prior probability closest to the target
toxicity level.
We used the extended CRM to address concerns about
having adequate data from lower dose levels in this sce-
nario where 100 % dose escalations are permitted and the
dose-toxicity relationship is unknown, and started at the
lowest dose level because a clear safety margin to the ex-
pected MTD dose is mandated in regulatory requirements
[7]. Goodman enrolled one, two and three patients to each
cohort prior to the first DLT and found no difference to
accuracy [11]. We elected to use two, assuming that dupli-
cate safety data from lower dose levels would provide
adequate information for escalation to proceed. Choices of
model calibration for the continual reassessment method
are specified in Table 1.
An algorithm that recommends the next dose is in-
creased by more than one dose at a time may cause con-
cerns about safety [11]. To explore this, we decided that
when the CRM recommends a dose increase of more
than one, we will continue with this recommendation.
For comparison, an analysis where the dose only increases
by one level will also be conducted. If the CRM recom-
mends a dose reduction of more than one, we will apply
this recommendation. We considered six prior skeleton
approaches; conservative, aggressive, step-up, dose-linear,
sigmoidal, and O’Quigley which are displayed in Fig. 1a.
We used the empiric dose-toxicity model for all ap-
proaches as we wanted to explore a range of relationships
between dose and toxicity. For the O’Quigley approach,
we standardised dose values and put these into the
hyperbolic distribution in order to determine the prior
probabilities for this method. The dose-linear approach
assumes the probability of DLT [P(DLT)] increases at
the same rate as dose. The step-up, dose-linear and sig-
moidal approaches were thought to roughly imitate a
more typical biological relationship between dose and
toxicity by assuming the difference in P(DLT) is dose-
proportional and hence greater between higher dose
levels than between lower dose levels, as O’Quigley et al.
did [12]. However with little knowledge on dose-toxicity,
it may be difficult to predict when the dose curve will rise
steeply. Therefore the relationship may be correct for an
Table 1 Model calibration for the continual reassessment method
Criteria Possible choices Our model
Dose-toxicity model Empiric, logistic, power Empiric
Prior distribution Gaussian, exponential Gaussian
Target toxicity level 0 to 100 % <33 %
Stopping rule Unlimited. A maximum of 6 patients at a single dose.
Prior skeleton Unlimited Conservative, aggressive, step-up, dose-linear, sigmoidal,
O’Quigley
Adaption - Extended CRM Allocate 1 to 3 patients to each cohort prior to the CRM Allocate 2 patients to each cohort prior to the CRM
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infinite dose range of the drug but possibly not for the
range used for the trial. The conservative and aggressive
approaches were chosen as they have an even difference
in P(DLT) between each dose level (log-linear to dose in
this example). The conservative approach requires more
knowledge that a dose is safe before moving onto the next
dose than the aggressive approach. The step-up, dose-
linear and sigmoidal approaches require little knowledge
that a lower dose is safe to escalate, but considerable
knowledge that a higher dose is safe to escalate.
Two further exploratory analyses were conducted. Firstly,
we examined the effect of changing the prior P(DLT)
values by adding 10 percentage points to each prior
P(DLT) in each prior skeleton approach and reran the
approaches. For instance, the conservative approach
has P(DLT) of 10 % and 30 % for the first two doses,
Fig. 1 Initial dose-toxicity curves and 95 % prediction intervals from prior skeleton approaches. The predicted probabilities of experiencing a DLT
and corresponding 95 % prediction intervals for each prior skeleton approach used in the extended CRM method prior to the inclusion of any
dose-toxicity data
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whereas the conservative + 10 percentage points approach
has 20 % and 40 % for these doses. Increased P(DLT)
should lead to slower dose-escalation as the higher doses
are further away from the target toxicity level line at the
start. Note for prior probabilities exceeding 100 %, the prior
probability was considered to be 99 %. For instance the
2000 mg BID prior probability was 96 % for the O’Quigley
approach and 99 % for the O’Quigley + 10 percentage
points approach. Secondly we reproduced the extended
CRM with the conservative approach but instead enrolled
three patients to each dose prior to the first DLT for further
comparison with the 3 + 3 method. This version of the ex-
tended CRM cannot recruit less than three patients in each
cohort prior to the first DLT, so may also be appropriate in
circumstances where it is desirable to have more data at
lower dose levels for other dose-dependent effects, such as
measure of biological activity to determine a maximum bio-
logical effective dose that may be below MTD.
Statistical analysis
We performed extended CRM analysis with the empiric
discrete dose-toxicity model, with a Gaussian prior dis-
tribution of mean 0 and variance 1.34 for each prior
skeleton approach on the exploratory dataset, using the
escalator package in R (https://www.r-project.org/). Target
toxicity level was set to <33 % to aid comparison with the
3 + 3 method. A dose was identified as the MTD when six
patients have already received this dose and the CRM rec-
ommended a 7th patient receive the same dose. This aids
comparison with the 3 + 3 method, because another dose
may be explored after six patients, but no more than 6
patients would be in a single cohort. The CRM model
choices are specified in Table 1. The 3 + 3 method was
also applied to the exploratory dataset, we assumed each
patient in a cohort begun their treatment simultaneously.
Each dose-escalation method will use the occurrence of
DLTs at each dose as specified in the exploratory dataset
(Table 2) i.e. the first patient allocated to 1000 mg QD
would experience a DLT. A worked example of the ex-
tended CRM method with the conservative approach is
provided in Appendix.
The dose escalation approaches were compared in
terms of identifying the true MTD, and the number or
patients who would receive suboptimal or toxic doses.
Results
In total, 28 patients were eligible and included in the ex-
ploratory dataset, six in each AZD3514 cohort from
250 mg QD to 1000 mg BID and four in the 2000 mg
BID cohort. Of the patients receiving between 250 mg
QD to 1000 mg BD AZD3514, one patient was not
included because they received less than 28 days of
treatment at one dose, and thirteen were not included
because we had already reached the maximum quota of
six patients per dose level. Eligible patients had a mean
age of 69 years (range 45–79).
Eight of the eligible patients (29 %) experienced a DLT
during treatment (Table 2, Fig. 2). These were: the first
patient who received 1000 mg QD; the second, fourth
and fifth patient who received 1000 mg BID; and all four
patients who received 2000 mg BID. No patients experi-
enced a DLT on 500 mg AZD3514 per day or less. This
suggests there is a clear positive relationship between
dose and toxicity and the dose-toxicity relationship is
steeper than any of our chosen priors. We observed
1000 mg BID and 2000 mg BID are intolerable as over
33 % of patients on these doses experienced a DLT
(1000 mg BID: 3/6 patients or 50 %, 2000 mg BID: 4/4
patients or 100 %). 1000 mg QD is the highest dose
where the toxicity is less than 33 %, so dose escalation
methods should identify this is the MTD. Therefore we
considered doses below 1000 mg QD as suboptimal.
Primary analysis
The number of patients required to identify the MTD
as well as the number and proportion of patients allo-
cated to suboptimal (250 mg QD and 500 mg QD) and
intolerable (1000 mg BID and 2000 mg BID) doses for
each prior skeleton approach is in Table 3. All methods
correctly identified 1000 mg QD as the MTD (Table 3).
However the CRM methods required 10 to 15 patients
to identify the MTD, whereas the 3 + 3 method required
18 patients. The CRM methods only allocated four pa-
tients to suboptimal doses, while the 3 + 3 method allo-
cated six patients. Four patients would have experienced
DLTs if the 3 + 3 design was used, compared to one to four
patients if the CRM method was used. No methods allo-
cated any patients to the most toxic dose 2000 mg BID.
Table 2 Occurrence of DLTs
AZD3514 dose Number
eligible
Number
of DLTs
Proportion that
experienced a DLT
Eligible patients experiencing DLT (DLT = D, No DLT = blank)
1st 2nd 3rd 4th 5th 6th
250 mg QD 6 0 0 %
500 mg QD 6 0 0 %
1000 mg QD 6 1 16.7 % D
1000 mg BID 6 3 50 % D D D
2000 mg BID 4 4 100 % D D D D - -
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There were no occurrences where any CRM method
recommended a dose level increase or reduction of
more than one. The sigmoidal approach required the
lowest number of patients (10) to correctly identify the
MTD of 1000 mg QD and allocated no patients to a
toxic dose, although in practice we may wish to allocate
patients at the next highest dose to assess if it is toler-
able. All other approaches allocated at least two patients
to the non-tolerated dose of 1000 mg BID. Of these, the
conservative approach required the least patients to de-
termine the MTD (12) and allocated the lowest number
of patients to toxic doses (2). The aggressive, step-up,
dose-linear and O’Quigley approaches required 15 pa-
tients to determine the MTD and allocated more pa-
tients to a toxic dose (5). Notably these approaches
allocated a fifth patient to 1000 mg BID despite two out
of four patients at this dose already experiencing a DLT.
One DLT would have been experienced if the sigmoidal
approach was used to escalate dose, two if the conserva-
tive approach was used and four if any other prior skel-
eton approach was used. There is considerably more
confidence in estimates of the P(DLT) at each dose in
the final dose-toxicity curves (Fig. 3a to f ) than the prior
dose-toxicity curves (Fig. 1a to f ), as expected. The final
dose-toxicity curves have similar distributions between
the lowest and second highest dose and prediction in-
tervals to each other and are somewhat similar to the
true distribution (Fig. 2). The P(DLT) varies consider-
ably for the highest dose, which is probably because no
patients were tested at this level. There were two not-
able differences, the P(DLT) for 1000 mg BID is notice-
ably higher in the sigmoidal and dose-linear approaches
and the aggressive approach did not achieve a strong
curve like the other approaches. The credible intervals
for the P(DLT) of the 1000 mg BID was widest in the
conservative and sigmoidal approaches, which is prob-
ably because less patients were tested at this dose then in
other approaches.
Exploratory analysis
Adding 10 percentage points to all priors in the sigmoidal,
step-up and aggressive approaches made no difference to
their dose allocation and all approaches still correctly iden-
tified the correct MTD, interestingly with the same number
of patients or less (Additional file 2). The dose-linear ap-
proach required one less patient to achieve the MTD,
which decreased the frequency of patients allocated to toxic
dose by one and in doing so reduced the number of DLTs
experienced from four to three. The conservative approach
also required one less patient to achieve the MTD, one add-
itional patient was allocated to a suboptimal dose, and two
less patients were allocated to toxic doses which reduced
the number of DLTs experienced from two to one. The
O’Quigley approach required five less patients to iden-
tify the MTD, and the number of patients allocated to
1000 mg BID (toxic dose) reduced from five to zero,
which reduced the number of DLTs experienced from
four to one. Adding 10 percentage points to each prior
made little difference to the final P(DLT) for the lowest
three doses and dose-toxicity distribution of any prior
skeleton approach (Additional file 1).
When the conservative approach was rerun with three pa-
tients allocated to each dose prior to the first DLT occurring,
the approach required five additional patients to determine
the DLT (Table 3). Two additional patients received subopti-
mal doses and three additional patients received toxic doses
of 1000 mg QD which would result in two more DLTs. This
approach allowed no reductions in suboptimal doses com-
pared to the 3 + 3 method but did allocate one less patient
Fig. 2 True dose toxicity curve. The observed proportion of DLTs at each dose level from the exploratory dataset
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Table 3 Comparison of dose escalation methods
Number of patients (Order of receiving dose – DLTs are bold) Number of patients
Method Prior skeleton approach MTD identified 250 Mg QD 500 Mg QD 1000 Mg QD 1000 Mg BID 2000 Mg BID Total Suboptimal
(<1000 mg QD)
Intolerable
(>1000 mg QD)
3 + 3 - 1000 Mg QD 3 (1, 2, 3) 3 (4, 5, 6) 6 (7, 8, 9, 10, 11, 12) 6 (13, 14, 15, 16, 17, 18) 0 18 6 6
Extended CRM −2a Conservative 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 8, 9, 10) 2 (11, 12) 0 12 4 2
Aggressive 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 10, 13, 15) 5 (8, 9, 11, 12, 14) 0 15 4 5
Step-up 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 8, 9, 14) 5 (10, 11, 12, 13, 15) 0 15 4 5
Dose-linear 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 8, 11, 15) 5 (9, 10, 12, 13, 14) 0 15 4 5
Sigmoidal 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 8, 9, 10) 0 0 10 4 0
O’Quigley 1000 Mg QD 2 (1, 2) 2 (3, 4) 6 (5, 6, 7, 8, 9, 10) 5 (11, 12, 13, 14, 15) 0 15 4 5
Extended CRM −3b Conservative 1000 Mg QD 3 (1, 2, 3) 3 (4, 5, 6) 6 (7, 8, 9, 10, 11, 14) 5 (12, 13, 15, 16, 17 0 17 6 5
aTwo patients in each cohort prior to CRM. bThree patients in each cohort prior to CRM
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Fig. 3 Final dose toxicity curves and 95 % prediction intervals for every CRM method. The predicted probabilities of experiencing a DLT and corresponding
95 % prediction intervals for each prior skeleton approach used in the extended CRM method after the MTD has been determined for the AZD3514 data
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to a toxic dose, which also resulted in one less patient
overall. The final dose toxicity curve (Fig. 3g) was similar
to that of the conservative approach with two patients at
each dose (Fig. 3a).
Discussion
This post-hoc analysis on clinical dose-escalation data
compared the CRM method with various prior skeleton
approaches and the 3 + 3 method. The results provide
further evidence the CRM method is more efficient and
may preserve safety compared to the 3 + 3 method as every
prior skeleton approach required less patients to identify
the MTD, and allocated less patients to suboptimal and
toxic doses. It is notable that the CRM outperformed the 3
+ 3 even though the true dose-toxicity curve was steeper
than any of our chosen prior skeleton approaches. We
found the underlying model of the dose-toxicity relation-
ship influences the number of patients allocated to toxic
doses, but in all cases the correct optimal dose was chosen.
To our knowledge this is the first study to compare
prior skeleton approaches in the CRM method. O’Quigley
& Chevret also found that even if prior probabilities are
underestimated or overestimated the performance of the
CRM will be at least as good as standard methods [16].
Lee & Cheung observed that most studies use the
O’Quigley et al. [12] prior skeleton approach without
providing justification [2]. Many dose escalation studies
that we identified did not display the prior probabilities
they used or justify how they obtained them.
For our data, the conservative prior skeleton approach
was more successful then the step-up and dose-linear
approaches as it allocated less patients to toxic doses des-
pite the original dose-toxicity curves of these approaches
being closer to the true relationship. This may suggest the
overall spacing between prior probabilities is a key factor
of the dose-toxicity relationship in the original prior com-
bination, and the spacing may be more important than
the overall shape of the curve. Another plausible dose-
toxicity relationship is the one used in the sigmoidal
approach, but no patients were allocated to 1000 mg BID
despite only one out of six patients at the dose below
experiencing a DLT. If the spacing between 1000 mg QD
and 1000 mg BID was closer, then some patients may have
been allocated to the next highest dose which highlights
the strong barrier to dose escalation that the steep part of
the curve presents. One concern was that the O’Quigley,
aggressive, step-up and dose-linear approaches allocated a
further patient to 1000 mg BID despite two out of four
patients on this dose experiencing a DLT. This could be
caused by insufficient spacing between the P(DLT) for
1000 mg QD and 1000 mg BID (10 % aggressive, 20 %
step-up, 25 % dose-linear and 29 % O’Quigley approaches)
or prior probabilities of the toxicity of the 1000 mg BID
dose not high enough (50 % dose-linear, 60 % aggressive,
64 % O’Quigley and 65 % step-up approaches). Notably in
the conservative and O’Quigley approaches when the
prior probability of 1000 mg BID was 64 % and 70 % re-
spectively, some patients received this dose, when it was
74 % and 80 % respectively (conservative + 10 percentage
points and O’Quigley + 10 percentage points approach) no
patients received this dose. The highest prior probability
to receive any dose was 75 % and was the 1000 mg BID
dose from the step-up + 10 percentage points approach.
To escalate faster and reduce the number of patients on
suboptimal doses, we could lower the P(DLT) prior prob-
abilities but this would put more patients at risk of a DLT,
which causes a suboptimal/toxic dose ethical dilemma.
Therefore choice of prior skeleton approach for studies
should partially depend on which of minimising suboptimal
or minimising toxic doses is more important. Daugherty et
al. reported a cancer trial where patients got to select their
own dose and found patients would chose the highest dose
even with knowledge of the increased toxicity risk and pa-
tients thought more about possible benefits than side
effects when choosing their dose [23].
Clinical opinion should also be used in decisions to recom-
mend the next dose to improve the flexibility of choice. We
identified two situations where investigators may have wished
to override the CRM decision. Firstly, where one dose is con-
sidered safe (i.e. target toxicity not exceeded), but at the dose
level above, either no patients (sigmoidal approach) or a small
number of patients (conservative approach) have been tested,
the investigators may wish to test more patients at the higher
dose, thus overriding the CRM decision. Secondly, other
CRM prior skeleton approaches allocated a patient to
1000 mg BID despite two of four patients who had already re-
ceived this dose experiencing a DLT, investigators may wish
to stop this extra patient receiving this dose. Including an
additional modification to the CRM method such as escal-
ation with overdose control (EWOC) may also prevent too
many patients receiving a toxic dose [24].
We chose a stopping rule to be a maximum of 6 patients
treated at a single dose and identified a dose as the MTD
when the CRM recommended a 7th patient to receive the
same dose. This enabled a direct comparison of CRM with
the 3 + 3 design. To increase confidence in dose-toxicity
relationship and the prediction of MTD, it is possible to al-
locate additional patients to dose levels. Clinical opinion is
also important in the 3 + 3 method. For the 1000 mg BID
dose, one out of the first three patients experienced a DLT.
For the 4th, 5th and 6th patients allocated to this dose, a
clinician may have suggested allowing time between these
patients receiving their first doses, which may prevent
more than one DLT occurring in these patients.
Since this study was designed to compare effects of
different models on MTD assessment, the scenario
chosen was one where toxicity is assumed to be the pri-
mary determinant of the recommended phase II dose.
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Pharmacodynamic response could be modelled in a
similar way and determination of a maximum biological
effective dose would be expected to raise similar issues
of rule-based systems versus statistically efficient model-
based systems or Bayesian approaches.
Strengths + limitations
This study has several strengths. It is a post-hoc ana-
lysis on a real phase 1 clinical trial, there were at
least six eligible patients at four doses, the probability
of DLT increased markedly with increased dose and
information on patient characteristics was available, and
we considered several skeleton scenarios that covered a
range of prior beliefs of toxicity. A limitation of this study
is that we did not consider time between each patient be-
ing allocated a dose. In practice, this process could be sped
up by allocating doses to two patients at a time.
Implications
This research has implications for future phase I tri-
als. Further support is provided for using the CRM
instead of standard methods. The importance of selecting
an appropriate prior dose-toxicity model has been shown.
Specifying a wide prediction interval for each prior prob-
ability allows the model to be influenced by the data so
highly accurate estimates of each prior probability may
not be essential to determine the true MTD. Several prior
dose-toxicity models have been proposed, and compared,
and recommendation made for their use in future trials.
Conclusions
The CRM model is more efficient and may expose less pa-
tients to toxic doses compared to the 3 + 3 method, even
when the optimal dose-toxicity curve is unknown. Choice
of the prior skeleton approach and initial estimates should
depend on whether minimizing the number of patients al-
located to suboptimal or toxic doses is more important.
Highly accurate initial estimates may not be essential to
determine the true MTD. This manuscript describes prior
dose-toxicity models that could be used when limited
dose-toxicity relationship data is available and raises the
importance of further exploration into this. It also reiter-
ates the importance of combining the CRM recommenda-
tions with clinical opinion for decisions to escalate/de-
escalate dose. We advise authors who are using CRM
methods to make available their initial priors and final
dose-toxicity graphs so optimal generic graphs can be de-
rived and to support the uptake of these methods.
Appendix
A worked example of the extended CRM with
conservative prior skeleton approach
The order of patients who experienced DLTs is in
Table 2. The original dose-toxicity curve of the
conservative approach and corresponding 95 % predic-
tion interval is below.
Two patients receive 250 mg QD. Neither experienced
a DLT so can escalate to next dose.
Two patients receive 500 mg QD. Neither experienced
a DLT so can escalate to next dose.
The first patient who receives 1000 mg QD experi-
ences a DLT.
The dose toxicity curve is updated with the above tox-
icity information as displayed below.
From now on, the CRM will be used to determine the
next dose.
Iteration 1
Fig. 4 The predicted probabilities of experiencing a DLT and
corresponding 95 % prediction intervals for the conservative
prior skeleton approach in the CRM method prior to the inclusion of
any dose-toxicity data
Fig. 5 The predicted probabilities of experiencing a DLT and
corresponding 95 % prediction intervals for the conservative
prior skeleton approach in the extended CRM method after the
inclusion of the first five AZD3514 patients
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The CRM recommends the next patient receives dose
3 (1000 mg QD) as this dose has the closest P(DLT) to
the target toxicity level (33 %).
The next patient receives 1000 mg QD, does not ex-
perience a DLT and the CRM method recommends the
next dose is dose 3 (1000 mg QD). This happens four
more times.
Iteration 6
The CRM recommends the next patient receives dose
4 (1000 mg BID). One patient receives this dose, does
not experience a DLT and the CRM method recommends
the next dose is dose 4 (1000 mg QD).
Iteration 7
The CRM recommends the next patient receives dose
4 (1000 mg BID). One patient receives this dose, experi-
ences a DLT and the CRM method recommends the
next dose is dose 3 (1000 mg QD).
Iteration 8
Six patients have already received 1000 mg QD and
this is the next recommended dose which meets our
stopping criteria. We stop the trial and 1000 mg QD is
identified as the MTD.
Additional files
Additional file 1: Comparison of dose escalation methods for + 10
percentage points approaches. (DOCX 32 kb)
Additional file 2: Final dose toxicity curves and 95 % prediction intervals
for every CRM method + 10 percentage points. Legend: The predicted
probabilities of experiencing a DLT and corresponding 95 % prediction
intervals for each prior skeleton + 10 % approach used in the
extended CRM method after the MTD has been determined for the
AZD3514 data. (ZIP 678 kb)
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